Pinned Tweet
🎙️ ConferenceHype turns major medical conferences & journals into AI-narrated video updates. YouTube and X for now.
🔔 Subscribe on YouTube
❤️ Like & follow here
💡 Got a conference, journal, or story idea? Reply or tag #ConferenceHype — we read
conferencehype.com
1
150
RSNA 2026 Preview 2: #RSNA26 @RSNA @RadNetImaging On the last screen before diagnosis, AI flagged the breast that later had cancer in 26.5% of women vs 5.1% for the other breast. Retrospective. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=hIz4b8Fo…
1
6
RSNA 2026 Preview 2: #RSNA26 @RSNA @RadNetImaging Assure AI breast screening: aggressive-cancer detection in dense breasts, relative rate 1.68 (95% CI 1.17-2.40) vs standard care. Company summary. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=hIz4b8Fo…
1
5
RSNA 2026 Preview 2: #RSNA26 @RSNA @RadNetImaging DeepHealth Thyroid Solution: radiologists kept all five AI-drafted descriptors in 88.7% of 187,292 nodules across 297 clinics. Talk Nov 29. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=hIz4b8Fo…
1
6
HLTH 2026 Update 3: #HLTHUSA @HLTHEVENT @CVSHealth GLP-1 year 3: medical costs down $9,400 per member, drug costs up $13,300, net up about $3,900. Modeled break-even: about $350 a month. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=euJXsvbT…
2
16
HLTH 2026 Update 3: #HLTHUSA @HLTHEVENT @CVSHealth @Aetna CVS Health study of matched Aetna members: GLP-1 users had 34-42% fewer hospital stays. Observational, not randomized. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=euJXsvbT…
2
12
ISA 2026 Update 2: #ISA2026 @ISA_Amyloidosis @Alnylam @BridgeBioPharma Indirect comparison, vutrisiran vs acoramidis: mortality HR 0.62 (95% CI 0.34-1.15), not statistically significant. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=sRXQWQu8…
35
ISA 2026 Update 2: #ISA2026 #Amyloidosis @ISA_Amyloidosis @intelliatx One-time nex-z gene editing in ATTRv polyneuropathy: mean serum TTR down 93.1% at month 48 (Phase 1, 33 treated). To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=sRXQWQu8…
14
CTOS 2026 Update 1: #CTOS2026 @ctosociety @inhibrx Ozekibart + irinotecan/temozolomide in relapsed Ewing sarcoma: ORR 62.7% in 51 evaluable, DCR 86.3%, median PFS 6.0 months (single-arm). To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=M8IXjIf4…
2
96
CTOS 2026 Update 1: #CTOS2026 @ctosociety @Immutep Eftisarc-Neo Phase 2, efti + pembrolizumab + radiotherapy before sarcoma surgery: 12-month disease-free survival 81.1% in 38 people; OS immature. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=M8IXjIf4…
2
134
CTAD 2026 Update 7: #CTAD26 @CTADconference @biogen @Eisai_SDGs Post hoc meta-analysis of 16 real-world lecanemab cohorts: pooled ARIA 12.4% vs 21.5% in Clarity AD; symptomatic ARIA 0.8% vs 2.8%. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=Sqz-_0mV…
1
1
77
CTAD 2026 Update 7: #CTAD26 @CTADconference @biogen @Eisai_SDGs Real-world LEADER, 560 on lecanemab: 76% lower progression to moderate/severe AD vs external control (HR 0.24). To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=Sqz-_0mV…
1
68
CTAD 2026 Update 6: #CTAD26 @CTADconference @biogen @ionispharma CELIA extension: diranersen 60 mg slowed CDR-SB decline 38% at week 96 vs original placebo (1.09 points), up from 26% at 18 months. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=xha5iTZ-…
1
3
459
CTAD 2026 Update 5: #CTAD26 @CTADconference Oral PRI-002, PRImus-AD Phase 2, 304 patients: missed week 48 CDR-SB goal; exploratory week 72 ADAS-Cog13 slowing 35.9% per protocol (p=0.022). To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=FB_Qr0Ss…
1
108
CTAD 2026 Update 5: #CTAD26 @CTADconference @AcadiaPharma Phase 2 RADIANT, remlifanserin for Alzheimer's psychosis: 44.0% vs 31.8% improved at week 6 (nominal); primary goal narrowly missed. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=FB_Qr0Ss…
61
SfN 2026 Update 3: #SfN26 @SfNtweets AAV2-NGF gene therapy for early Alzheimer's: gene still active 15 years on, no toxicity in 10 brains; Phase 2 did not slow decline. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=CK5ZX2Z7…
72
SfN 2026 Update 3: #SfN26 @SfNtweets Open-label Phase 2, NouvNeu001 cells in advanced Parkinson's: off-medication motor score 58.47 to 41.65 at 6 months (n=17). To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=CK5ZX2Z7…
62
SfN 2026 Update 3: #SfN26 @SfNtweets @NervgenP Phase 1b/2a, 20 people with chronic spinal cord injury: NVG-291 raised hand-muscle motor responses 9.43% of max at week 12 (p=0.0155). To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=CK5ZX2Z7…
160
ObesityWeek 2026 Update 11: #OW2026 @ObesityWeek @Veru_Pharma QUALITY post hoc, ages 65+: enobosarm plus semaglutide raised stair-climb power 16.48% vs semaglutide alone at 16 weeks. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=63Krf8Dk…
2
31
ObesityWeek 2026 Update 11: #OW2026 @ObesitySociety @RhythmPharma 2-year TRANSCEND extension, setmelanotide in acquired hypothalamic obesity: BMI -18.8% continuous, -16.5% after placebo switch. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=63Krf8Dk…
2
35
CTAD 2026 Update 4: #CTAD26 @CTADconference @biogen Five-year Clarity AD: lecanemab 2.05 points better on CDR-SB vs external ADNI cohort; 36% lower next-stage risk. No placebo after 18 months. To learn something new follow us and subscribe on YouTube: youtube.com/watch?v=nnXzfdCt…
3
136
